1-benzhydryl-3-methyl-piperazine | 95558-04-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzhydryl-3-methyl-piperazine
• 英文别名: 1-diphenylmethyl-3-methyl-piperazine；1-diphenylmethyl-3-methylpiperazine；1-benzhydryl-3-methylpiperazine
• CAS: 95558-04-6
• 化学式: C₁₈H₂₂N₂
• 分子量: 266.386
• InChiKey: HRLOVHUUKIJALJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-溴丁基)邻苯二甲酰亚胺 、 1-benzhydryl-3-methyl-piperazine 在 sodium iodide 、 potassium carbonate 作用下， 以 水 、 丁酮 为溶剂， 生成 2-[4-(4-diphenylmethyl-2-methyl-1-piperazinyl)butyl]phthalimide
  参考文献：
  名称：

  .omega.-(3-pyridyl)alkenamide derivatives and anti-allergenic

  摘要：

  该公式化合物为：其中X为烷基或--(CR6.dbd.CR7)r--，其中R6为H、烷基或苯基，R7为H、烷基、氰基或苯基，r为1或2；A为烷基或至少有一个双键中断的烷基；R1为H、卤素、烷基、烷氧基、烷基硫基、环烷氧基、环烷硫基、烷氧羰基、羧基、苯基、苯氧基、苯硫基、3-吡啶氧基或3-吡啶硫基；R2为H、羟基、烷酰氧基或烷氧羰氧基，或相邻的R1和R2可结合形成四亚甲基或--CH2OCR8R9O--（R8和R9为烷基）；R3为H、烷基或羟基烷基；R4为H或烷基；R5为苯基、杂环芳基或--(CH2)m--CHR10R11（R10为H或苯基，R11为苯基或吡啶基，m为0至2）；p为0或1；q为2或3；苯基或基团可选择性地被取代，以及其盐，以及制备方法和含有该化合物的药物组合物。所述化合物及其盐主要通过5-脂氧合酶抑制活性、抗组胺活性和/或抑制化学介质释放活性表现出优异的抗过敏活性，对于治疗过敏性疾病具有用处。

  公开号：

  US04778796A1

文献信息

• [EN] HETEROCYCLICALKYL DERIVATIVE COMPOUNDS AS SELECTIVE HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS D'ALKYLE HÉTÉROCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2016190630A1

  公开（公告）日：2016-12-01

  The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.

  本发明涉及具有组蛋白去乙酰化酶（HDAC）抑制活性的新型杂环烷基衍生物，其光学异构体或其药学上可接受的盐，以及其用于制备药物、含有该药物的药物组合物、使用该组合物治疗疾病的方法，以及制备新型杂环烷基衍生物的方法。根据本发明的新型杂环烷基衍生物是选择性组蛋白去乙酰化酶（HDAC）抑制剂，可有效用于治疗组蛋白去乙酰化酶介导的疾病，如细胞增殖性疾病、炎症性疾病、常染色体显性疾病、遗传代谢性疾病、自身免疫性疾病、急性/慢性神经疾病、肥大、心力衰竭、眼部疾病或神经退行性疾病。
• Indole-type derivatives as inhibitors of p38 kinase
  申请人：——

  公开号：US20040142940A1

  公开（公告）日：2004-07-22

  The invention is directed to methods to inhibit p38-&agr; kinase using compounds comprising a phenyl or thienyl coupled through a piperidine or piperazine nucleus to an indole residue wherein the indole residue mandatorily has a substituent on the ring nitrogen which is an amino or substituted amino group.

  该发明涉及使用含有苯基或噻吩基通过哌啶或哌嗪核与吲哚残基相连的化合物来抑制p38-α激酶的方法，其中吲哚残基上强制地具有环氮上的氨基或取代氨基基团。
• .omega.-(3-pyridyl)alkenamide derivatives and anti-allergenic
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04778796A1

  公开（公告）日：1988-10-18

  Compounds of the formula: ##STR1## wherein X is alkylene or --(CR.sub.6 .dbd.CR.sub.7).sub.r -- wherein R.sub.6 is H, alkyl or phenyl, R.sub.7 is H, alkyl, cyano or phenyl, and r is 1 or 2; A is alkylene or alkylene interrupted by at least one double bond; R.sub.1 is H, halogen, alkyl, alkoxy, alkylthio, cycloalkyloxy, cycloalkylthio, alkoxycarbonyl, carboxy, phenyl, phenoxy, phenylthio, 3-pyridyloxy or 3-pyridylthio; R.sub.2 is H, hydroxy, alkanoyloxy or alkoxycarbonyloxy, or adjacent R.sub.1 and R.sub.2 may combine to form tetramethylene or --CH.sub.2 OCR.sub.8 R.sub.9 O-- (R.sub.8 and R.sub.9 are alkyl); R.sub.3 is H, alkyl or hydroxyalkyl; R.sub.4 is H or alkyl; R.sub.5 is phenyl, heteroaryl or --(CH.sub.2).sub.m --CHR.sub.10 R.sub.11 (R.sub.10 is H or phenyl, R.sub.11 is phenyl or pyridyl and m is 0 to 2); p is 0 or 1; and q is 2 or 3; the phenyl group or moiety being optionally substituted, and a salt thereof, process for the preparation thereof, and pharmaceutical composition containing the same. Said compounds and salts thereof show excellent antiallergic activity mainly through 5-lipoxygenase inhibiting activity, antihistamine activity and/or inhibitory activity against chemical mediator release and useful for treatment of allergic diseases.

  该公式化合物为：其中X为烷基或--(CR6.dbd.CR7)r--，其中R6为H、烷基或苯基，R7为H、烷基、氰基或苯基，r为1或2；A为烷基或至少有一个双键中断的烷基；R1为H、卤素、烷基、烷氧基、烷基硫基、环烷氧基、环烷硫基、烷氧羰基、羧基、苯基、苯氧基、苯硫基、3-吡啶氧基或3-吡啶硫基；R2为H、羟基、烷酰氧基或烷氧羰氧基，或相邻的R1和R2可结合形成四亚甲基或--CH2OCR8R9O--（R8和R9为烷基）；R3为H、烷基或羟基烷基；R4为H或烷基；R5为苯基、杂环芳基或--(CH2)m--CHR10R11（R10为H或苯基，R11为苯基或吡啶基，m为0至2）；p为0或1；q为2或3；苯基或基团可选择性地被取代，以及其盐，以及制备方法和含有该化合物的药物组合物。所述化合物及其盐主要通过5-脂氧合酶抑制活性、抗组胺活性和/或抑制化学介质释放活性表现出优异的抗过敏活性，对于治疗过敏性疾病具有用处。
• Glycine transporter-1 inhibitors
  申请人：Hitchcock Stephen

  公开号：US20080004289A1

  公开（公告）日：2008-01-03

  The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了一种甘氨酸转运蛋白1（以下简称为GlyT-1）抑制剂的化合物，因此可用于治疗通过抑制GlyT1可治疗的疾病，如与精神分裂症、注意力缺陷多动障碍（ADHD）、轻度认知障碍（MCI）等相关的认知障碍。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
• Calcium channel blockers comprising two benzhydril moieties
  申请人：Snutch P. Terrance

  公开号：US20060084660A1

  公开（公告）日：2006-04-20

  Certain piperazine compounds are described which are useful in altering calcium channel activity.

  描述了某些哌嗪化合物，其在改变钙通道活性方面是有用的。